Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-123447
Filing Date
2024-11-07
Accepted
2024-11-07 16:41:22
Documents
64
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q avir-20240930.htm   iXBRL 10-Q 2105556
2 EX-31.1 avir-ex31_1.htm EX-31.1 14493
3 EX-31.2 avir-ex31_2.htm EX-31.2 14708
4 EX-32.1 avir-ex32_1.htm EX-32.1 10000
5 EX-32.2 avir-ex32_2.htm EX-32.2 9359
  Complete submission text file 0000950170-24-123447.txt   7226198

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT avir-20240930.xsd EX-101.SCH 912216
66 EXTRACTED XBRL INSTANCE DOCUMENT avir-20240930_htm.xml XML 1130424
Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Filer) CIK: 0001593899 (see all company filings)

EIN.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39661 | Film No.: 241436629
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)